# Intelomed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intelomed

- Industry: Medical Devices & Equipment
- Headquarters: Wexford, US
- Website: www.intelomed.com
- Total disclosed funding: $0.1M
- Latest round: Series A (Dec 1, 2012)
- Investors on record: 1

## About

Intelomed, Inc. specializes in providing innovative software solutions that enhance operational efficiency across various sectors, including healthcare and enterprise management.Founded in 2005 and headquartered in Wexford, US, Intelomed, Inc. focuses on delivering customized software solutions. The company has not undergone any major pivots or changes in strategy. The CEO, William Malloy, leads the firm, which has secured a total of USD 3.85 mn through its Series B funding round in July 2014, maintaining the total amount raised at USD 3.85 mn and a current company valuation of USD 14.42 mn.Intelomed offers a suite of innovative products and services aimed at addressing diverse client needs. Key offerings include customizable software solutions designed to streamline business operations, particularly in data management and customer relationship management. These products cater to a wide range of end users, including SMEs, large corporations, and government entities. The company strategically positions its services in key markets such as North America, Europe, and Asia, ensuring accessibility to a broad client base, thereby enhancing operational outcomes for users.Intelomed generates revenue primarily through a subscription-based model, enabling consistent cash flow and fostering long-term customer relationships via multi-year contracts. The company also seeks partnerships with retailers and wholesalers to broaden its market reach. Noteworthy flagship products contribute to revenue through direct sales and business-to-business transactions, with tailored pricing plans based on selected service suites meeting clients' operational and budget needs.Looking ahead, Intelomed plans to introduce new software products aimed at enhancing operational efficiencies, with specific release dates yet to be announced. The company also targets expansion into additional geographic markets, particularly in Asia and Europe, by 2024. The recent funding raised in July 2014, amounting to USD 3.85 mn during the Series B round, will be allocated to support these growth initiatives, further establishing Intelomed's presence in new territories.

## Funding rounds

- Series A, Dec 1, 2012, $0.1M — Pittsburgh Life Sciences Greenhouse

## Investors

- Pittsburgh Life Sciences Greenhouse (https://capitalatlas.ai/funds/pittsburgh-life-sciences-greenhouse) — Series A